Diego A. Díaz García, Medical Oncologist, CEO and Founder at CánCare – Advanced Specialty in Oncology, shared a post on LinkedIn:
“Engineering Platelets as Cancer Therapeutics.
Platelets shape tumour biology through direct cell interactions, soluble mediators, and extracellular vesicles. Their context-dependent pro and antitumour effects limit simple inhibition strategies and support therapeutic reprogramming.
Advances in genetic and chemical engineering now enable multifunctional modification while preserving native properties. Engineered platelets may act as targeted drug delivery systems or as active modulators of tumour progression, with potential for autologous and allogeneic use.
Clinical translation requires control of activation, scalable manufacturing, and robust safety evaluation.”
Title: Engineering platelets as cancer therapeutics
Authors: Authors: Yu Chen, Tyler Wolter, Zhen Gu, Quanyin Hu
Read the full article.
Other articles featuring Diego A. Díaz García on OncoDaily.
